Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

North 51

- PMLiVE

Lilly and MeiraGTx partner in $475m ophthalmology deal

The companies will develop and commercialise therapies for genetic conditions

- PMLiVE

Merck to expand ophthalmology pipeline with acquisition of EyeBio in deal worth up to $3bn

Merck will gain access to EyeBio’s Restoret to prevent and treat retinal vascular leakage-associated vision loss

- PMLiVE

Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics

The company will gain the rights to use 4DMT’s gene therapy vector for at least one target

- PMLiVE

Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn

The transaction includes the Swiss drugmaker’s anti-inflammatory eye drop Xiidra

- PMLiVE

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Bayer's Eylea remains the drug to beat, however

- PMLiVE

Astellas: Ten years young

Ken Jones and Sef Kurstjens on the company's progress and plans

- PMLiVE

Pfizer to form specialty drugs unit after Allergan takeover

Will merge its consumer portfolio with Allergan's ophthalmology and aesthetics brands

- PMLiVE

The BMJ weighs in on Avastin/Lucentis debate

The UK’s leading medical journal says Avastin should be used for wet AMD to cut costs

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

- PMLiVE

New eye indication for Allergan’s Ozurdex

EU approval extends the drug's use to diabetic macular oedema

- PMLiVE

Alcon wins initial NICE backing for Jetrea in rare eye condition

Would be first alternative to surgery available to vitreomacular traction patients in England and Wales

- PMLiVE

Valeant buys Bausch + Lomb for $8.7bn

Biggest deal yet for acquisition-hungry Canadian pharma company

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links